4-Fluoro-4-deoxy-epiinositol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-Fluoro-4-deoxy-epiinositol
• 英文别名: 6-fluorocyclohexane-1,2,3,4,5-pentol
• 化学式: C₆H₁₁FO₅
• mdl: MFCD24390359
• 分子量: 182.15
• InChiKey: PDTJJYSBSOKEOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.7
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  101
• 氢给体数：
  5
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  [(3R,6R)-2-fluoro-3,4,5,6-tetrakis(phenylmethoxy)cyclohexyl]oxymethylbenzene 、 氢溴酸 、 二氯甲烷 以51%的产率得到
  参考文献：
  名称：

  LOWE, GORDON;MCPHEE, FIONA, J. CHEM. SOC. PERKIN TRANS. 1,(1991) N, C. 1249-1253

  摘要：

  DOI：

文献信息

• [EN] ACETYLATED PRODRUGS FOR DELIVERY ACROSS THE BLOOD-BRAIN BARRIER<br/>[FR] PROMÉDICAMENTS ACÉTYLÉS POUR ADMINISTRATION À TRAVERS LA BARRIÈRE HÉMATO-ENCÉPHALIQUE
  申请人：MASSACHUSETTS GEN HOSPITAL

  公开号：WO2019204808A1

  公开（公告）日：2019-10-24

  The present disclosure relates to pharmaceutical compositions including a compound derived from a parent compound having a hydroxyl or amino moiety, wherein the hydroxyl in the parent compound is presented as an ester in the compound or the amino in the parent compound is presented as an amide in the compound, and their use to prevent or treat neurological disease.

  本公开涉及包括从具有羟基或氨基团的母化合物衍生的化合物的制药组合物，其中母化合物中的羟基在化合物中呈酯形式，或母化合物中的氨基在化合物中呈酰胺形式，并且它们的用途是预防或治疗神经系统疾病。
• CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT
  申请人：Elmaleh David R.

  公开号：US20140140927A1

  公开（公告）日：2014-05-22

  Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula: wherein X is OH, C 1 -C 6 alkoxyl; Y and Z are independently selected from a C 1 -C 6 alkyl, C 1 -C 6 alkoxyl, halogen, un-substituted or C1-C6 substituted amine, 18 F, 19 F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.

  本发明揭示了一种新型的克罗莫林类似物，可用作检测动脉粥样硬化斑块和治疗动脉粥样硬化和阿尔茨海默病的成像剂，并揭示了制备克罗莫林类似物的方法。克罗莫林类似物的一般式如下：其中X为OH，C1-C6烷氧基；Y和Z分别选择自C1-C6烷基，C1-C6烷氧基，卤素，未取代或C1-C6取代胺，18F，19F或H；n为1，2或3；对于结构（I），如果n均为1且Y和Z均为H且X为OH。
• Cromolyn derivatives and related methods of imaging and treatment
  申请人：The General Hospital Corporation

  公开号：US10188757B2

  公开（公告）日：2019-01-29

  Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula; wherein X is OH, C1-C6 alkoxyl; Y and Z are independently selected from a C1-C6 alkyl, C1-C6 alkoxyl, halogen, mi-substituted or C1-C6 substituted amine, 18F, 19F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.

  本发明公开了可用作检测动脉粥样硬化斑块和治疗动脉粥样硬化及阿尔茨海默氏症的成像剂的新型色瑞林类似物，以及制造色瑞林类似物的方法。色甘宁类似物具有通式； 其中 X 是 OH、C1-C6 烷氧基；Y 和 Z 独立选自 C1-C6 烷基、C1-C6 烷氧基、卤素、mi-取代或 C1-C6 取代的胺、18F、19F 或 H；n 是 1、2 或 3；对于结构 (I)，如果 n 均为 1 且 Y 和 Z 均为 H，则 X 是 OH。
• Combination therapies for the treatment of Alzheimer's disease and related disorders
  申请人：The General Hospital Corporation

  公开号：US10398704B2

  公开（公告）日：2019-09-03

  The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.

  本发明涉及治疗阿尔茨海默氏症或淀粉样变性相关病理状况的组合疗法，包括联合施用治疗有效量的第一种化合物和治疗有效量的第二种化合物。在某些实施方案中，第一种化合物或第二种化合物抑制AB肽聚合；抗炎；改善认知功能、情绪或社会行为；与Tau或α-突触核蛋白相关；或调节淀粉样肽冲洗。
• Combination therapies for the treatment of Alzheimer'S disease and related disorders
  申请人：The General Hospital Corporation

  公开号：US10413551B2

  公开（公告）日：2019-09-17

  The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.

  本发明涉及治疗阿尔茨海默氏症或淀粉样变性相关病理状况的组合疗法，包括联合施用治疗有效量的第一种化合物和治疗有效量的第二种化合物。在某些实施方案中，第一种化合物或第二种化合物抑制AB肽聚合；抗炎；改善认知功能、情绪或社会行为；与Tau或α-突触核蛋白相关；或调节淀粉样肽冲洗。